Scilex Reports Efficacy and Safety Results of Semdexa (SP-102) P-III (C.L.E.A.R.) Program for Sciatica Pain Management
Shots:
- The P-III (C.L.E.A.R.) program evaluates the safety & analgesic effects of a single & repeat transforaminal inj. of SP-102 vs PBO in 401 patients with lumbosacral radicular pain or sciatica
- The results showed that patients experienced a rapid onset of pain relief as measured by NPRS of avg. daily pain in affected leg @ first 4wks., following a single transforaminal inj. The 2EPs of ODI showed a 28% improvement @4wks. on SP-102 over baseline
- The company plans to discuss with the US FDA in 2022 for licensure application & BTD. If SP-102 will be approved by the US FDA, the product will be available in a pre-filled syringe formulation & will be given as an epidural inj. for sciatica
Ref: Sorrento Therapeutics | Image: Scilex
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
